The BTK Inhibitor Zanubrutinib (BGB-3111) Demonstrated Synergies With Other Anti-Lymphoma Targeted Agents

Haematologica - Italy
doi 10.3324/haematol.2018.214759
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Brutons Tyrosine Kinase

English

Bruton's Tyrosine Kinase (Btk) Inhibitor BGB-3111 Demonstrates High Very Good Partial Response (Vgpr) Rate in Patients With Waldenström Macroglobulinemia (Wm)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

Differential Effects of BTK Inhibitors Ibrutinib and Zanubrutinib on NK Cell Effector Function in Patients With Mantle Cell Lymphoma

Haematologica
Hematology
2019English

Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2015English

A Head-To-Head Phase 3 Study Comparing BGB-3111 and Ibrutinib in Patients With Waldenström Macroglobulinemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Expanding Horizons in the Treatment of Mantle Cell Lymphoma: Ibrutinib a Novel BTK-targeting Inhibitor

International Journal of Basic & Clinical Pharmacology
2014English

Copanlisib Synergies With Conventional and Targeted Agents Including Venetoclax in Preclinical Models of B- And T-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy